Healthcare [ 5/13 ] | Biotechnology [ 44/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 13, 23 | 0.06 Increased by +113.28% | -0.26 Increased by +123.08% |
| Aug 10, 23 | -0.52 Decreased by -1.63 K% | -0.29 Decreased by -79.31% |
| May 12, 23 | -1.35 Decreased by -2.6 K% | -0.13 Decreased by -938.46% |
| Mar 31, 23 | -0.75 Decreased by -1.4 K% | -0.15 Decreased by -400% |
| Nov 10, 22 | -0.45 Increased by +39.77% | -0.6 Increased by +24.72% |
| Aug 15, 22 | -0.03 Increased by +96.67% | -0.6 Increased by +95% |
| May 16, 22 | -0.05 Increased by +94.44% | -0.04 Decreased by -25% |
| Mar 25, 22 | -0.05 Increased by +94.44% | -0.04 Decreased by -25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | 526 K Increased by +179.7% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -4.01 M Decreased by -564.51% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -8.71 M Decreased by -204.83% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | 5.01 M Increased by +649.18% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -660 K Increased by +24.23% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -603 K Increased by +36.46% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -2.86 M Decreased by -186.27% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -913 K Increased by +8.06% | Decreased by N/A% Decreased by N/A% |
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.